Business
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
W. Michael Flanagan, Ph.D. named chief scientific and technical officer SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a
About this update from Atrium Therapeutics, Inc.
[{"type":"text","content":"W. Michael Flanagan, Ph.D. named chief scientific and technical officer\nSAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D. has been appointed to the board of directors of the company and is transitioning from chief scientific officer into the role of distinguished scientist and strategic leader, remaining a key member of Avidity's team. W. Michael Flanagan, Ph.D., has been promoted from chief technical officer to chief scientific and technical officer.\n\n \n \n \n \n \n \n\n \n\"On behalf of Avidity's Board of Directors, we are grateful to Art for his scientific leadership, invaluable contributions in developing AOCs, life-long commitment to patients and dedication to our mission of revolutionizing the delivery of RNA therapeutics,\" said Troy Wilson, Ph.D., J.D., co-founder and chairman of the board of directors at Avidity Biosciences. \"We are delighted to appoint Art to our Board of Directors, and we look forward to his continued scientific expertise and guidance as we grow Avidity, advance clinical development programs and expand the utility of the AOC platform.\"\n\"Art's vision, scientific expertise and leadership as our chief scientific officer has been instrumental in building the company that we are today. With his perseverance and scientific prowess, we were able to demonstrate the first ever successful targeted delivery of RNA into muscle, a revolutionary advancement for Avidity and the RNA field. It is my distinct pleasure and privilege to work alongside Art and to now have him as a valued member of our Board. On behalf of all of us here at Avidity, we extend our heartfelt thanks to Art for his enormous contributions to Avidity and the field of RNA,\" said Sarah Boyce, president and chief executive officer at Avidity. \"We extend our congratulations to Mike on his promotion to chief scientific and technical officer. He has worked alongside Art for the last two years and is an instrumental leader within research and across Avidity. We look forward to his continued leadership in research and technical operations as we advance and expand our AOC programs.\"\n\"I am honored to be joining Avidity's prestigious bo...